As discussed at the end of January, Myriad has given up its Quixotic quest to validate its BRCA gene testing franchise and has abandoned its several lawsuits . With its agreement to dismiss actions against Ambry Genetics, LabCorp, Invitae, and Pathway Genomics, the earlier settlement agreement reached with Gene-by-Gene , and a separate settlement with Counsyl, the only actions remaining before the Utah court were against Quest and GenDx.